Takeda Pharmaceutical Ltd ADR (TAK)

Apr 1, 2025, 2:27 PM EDT - 1 day ago

Takeda & Protagonist: Rusfertide Clinical Success Bolsters Investment Returns

Mar 13, 2025, 3:45 AM EDT - 21 days ago

Takeda: Buy Into Future Drug Pipeline Potential, Despite Recent Profit Headwinds

Mar 3, 2025, 6:45 AM EST - 4 weeks ago

Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera

PTGX

Feb 24, 2025, 3:01 AM EST - 5 weeks ago

The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE)

Jan 31, 2025, 8:30 AM EST - 2 months ago

Strong Q3, Improved Guidance Are Signs Takeda Pharmaceutical May Be Undervalued

Jan 30, 2025, 4:45 PM EST - 2 months ago

Takeda Pharmaceutical Company Limited (TAK) Q3 2025 Earnings Call Transcript

Jan 30, 2025, 9:00 AM EST - 2 months ago

Suffolk Celebrates Topping off for a Game-Changing New Takeda Facility in Kendall Square Where Science, Art and Community Will Converge

Jan 30, 2025, 2:04 AM EST - 2 months ago

Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026

Jan 30, 2025, 1:43 AM EST - 2 months ago

Japan's Takeda says Q3 profit slid 38%, trailing analyst estimates

Jan 30, 2025, 1:35 AM EST - 2 months ago

Takeda Delivers Strong Third-Quarter FY2024 Results; Raises Full Year Outlook, Forecasting Revenue and Core Operating Profit Margin Growth

Jan 23, 2025, 7:14 PM EST - 2 months ago

Takeda-backed Ascentage Pharma aims to raise $126 mln in US IPO

Jan 21, 2025, 6:24 AM EST - 2 months ago

Takeda-backed Ascentage Pharma targets $1.75 billion valuation in US IPO

Dec 27, 2024, 1:00 AM EST - 3 months ago

Takeda Announces Approval of HYQVIA® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

Dec 12, 2024, 5:30 PM EST - 3 months ago

Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas

Dec 7, 2024, 8:00 AM EST - 4 months ago

Takeda Pharmaceutical: Dividend Yield Is High But Hides Pitfalls Especially For US Investors

Dec 3, 2024, 12:37 PM EST - 4 months ago

Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst

KROS

Dec 3, 2024, 7:00 AM EST - 4 months ago

Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics

KROS

Nov 20, 2024, 11:30 AM EST - 4 months ago

Alloy Therapeutics Signs Collaboration and License Agreement with Takeda to Develop Cell Therapy Platform

Nov 15, 2024, 3:33 PM EST - 4 months ago

Hennessy Japan Fund's Masa Takeda on the top Japanese stocks investors should watch

Oct 31, 2024, 11:02 PM EDT - 5 months ago

Takeda Pharmaceutical Company Limited (TAK) Q2 2025 Earnings Call Transcript

Oct 31, 2024, 2:15 AM EDT - 5 months ago

Japan's Takeda returns to Q2 profit as drugmaker recovers from impairments

Oct 31, 2024, 2:05 AM EDT - 5 months ago

Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook

Oct 24, 2024, 8:00 AM EDT - 5 months ago

Takeda and Boston Medical Center Announce Innovative Collaboration to Help Tackle Decarbonization Across Health Care Ecosystem

Oct 7, 2024, 9:36 AM EDT - 6 months ago

Takeda Pharmaceuticals: An Interesting Option For Income Investors

Sep 26, 2024, 8:30 AM EDT - 6 months ago

Tempus Announces Expansion of Collaboration with Takeda to Leverage Multimodal Real-World Datasets and Biological Model Systems in Oncology Research and Development

TEM

Sep 24, 2024, 3:00 AM EDT - 6 months ago

Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer

Sep 19, 2024, 8:00 AM EDT - 6 months ago

Takeda to Present Additional Clinical Trial Study Data Highlighting the Impact of Orexin Agonist TAK-861 on the Burden of Narcolepsy at Sleep Europe 2024

Sep 18, 2024, 10:00 AM EDT - 7 months ago

Takeda Commits Over $32 Million in Five New Global Corporate Social Responsibility Partnerships to Further Drive Health Impact in 93 Countries

Sep 4, 2024, 7:00 AM EDT - 7 months ago

US allows increased production of Takeda's ADHD drug to address shortage

Aug 12, 2024, 10:42 AM EDT - 8 months ago

Ascendis' Hypoparathyroidism Drug Scores FDA Approval As First and Only Treatment, Replacing Takeda's Drug Discontinued Due To Supply Issues

Aug 7, 2024, 2:29 PM EDT - 8 months ago

Why Is Japanese Drugmaker Takeda Pharmaceutical Stock Trading Higher On Wednesday?

Aug 7, 2024, 6:45 AM EDT - 8 months ago

Takeda Receives European Commission Approval for ADZYNMA®▼ (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Aug 2, 2024, 3:21 PM EDT - 8 months ago

Takeda Pharmaceutical Company Limited (TAK) Q1 2025 Earnings Call Transcript

Aug 1, 2024, 8:00 AM EDT - 8 months ago

BostonGene Announces Partnership with Takeda to Evaluate Immunotherapies Using AI-Powered Molecular Profiling

Jul 31, 2024, 2:06 AM EDT - 8 months ago

Takeda Announces First Quarter FY2024 Results - Strong Performance by Growth & Launch Products; Advancements in Promising Late-Stage Pipeline

Jul 19, 2024, 9:56 AM EDT - 9 months ago

Takeda's AI-Powered Strategy To Optimize Operations And Accelerate Its Pipeline

Jul 17, 2024, 8:15 AM EDT - 9 months ago

nference Establishes AI Initiative with Takeda to Advance Precision Medicine in Inflammatory Bowel Disease

Jun 26, 2024, 3:05 AM EDT - 10 months ago

Takeda Announces New Assignments of Directors

Jun 25, 2024, 8:09 PM EDT - 10 months ago

Takeda To Keep Pushing for China Biotech Partnership

Jun 24, 2024, 3:00 AM EDT - 10 months ago

Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies

Jun 22, 2024, 10:30 PM EDT - 10 months ago

Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia

Jun 21, 2024, 4:00 PM EDT - 10 months ago

Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer

Jun 21, 2024, 1:47 AM EDT - 10 months ago

Takeda gives Sun Pharma, Cipla rights to commercialize gastro drug in India

Jun 20, 2024, 9:15 PM EDT - 10 months ago

Ascentage Pharma Announces Closing of US$75 Million Equity Investment by Takeda

Jun 18, 2024, 8:00 AM EDT - 10 months ago

Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting

Jun 17, 2024, 8:58 AM EDT - 10 months ago

What's Going On With Ovid Therapeutics After Takeda's Two Phase 3 Epilepsy Studies Fail?

OVID

Jun 17, 2024, 7:11 AM EDT - 10 months ago

Takeda's seizure drug fails to meet main goal in late-stage studies

Jun 17, 2024, 6:45 AM EDT - 10 months ago

Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome

Jun 14, 2024, 9:13 AM EDT - 10 months ago

Ascentage Pharma Signs Option Agreement with Takeda to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)

Jun 14, 2024, 8:00 AM EDT - 10 months ago

Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)